炔雌醇环丙孕酮治疗多囊卵巢综合征(PCOS)伴不孕患者的临床疗效

The Clinical Efficacy of Ethinylestradiol and Cyproterone Acetate in Patients with PCOS and Sterility

目的:观察评价炔雌醇环丙孕酮在治疗多囊卵巢综合征(Polycystic ovary syndrome,PCOS)伴不孕患者中的临床疗效。方法:选取2012年1月-2014年10月本院收治的80例多囊卵巢综合征伴不孕患者为研究对象,所有患者均符合临床关于多囊卵巢综合征伴不孕的相关诊断标准,将80例患者随机分为观察组与对照组,每组各40例。对照组采用克罗米芬直接促排卵法,观察组在此基础上给予炔雌醇环丙孕酮。结果:治疗后观察组患者的卵泡数目及卵巢体积均显著低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后观察组患者的血清LH、T及FSH水平均显著低于对照组,两组比较差异有统计学意义(P<0.05)。观察组患者排卵率与妊娠率分别为82.5%、32.5%,对照组分别为52.5%、17.5%,组间比较观察组排卵率与妊娠率均显著高于对照组,两组比较差异有统计学意义(P<0.05)。结论:采用炔雌醇环丙孕酮片联合克罗米芬促排卵法治疗多囊卵巢综合征伴不孕,能有效降低血清性激素水平,恢复患者月经周期,促进排卵,提高妊娠率,具有较高的临床推广和应用价值。

Objective：To observe the clinical efficacy of ethinylestradiol and cyproterone acetate in patients with PCOS and sterility.Method：80 patients with PCOS and sterility treated from January 2012 to October 2014 in our hospital were selected.According to the related diagnostic criteria,the patients were randomly divided into observation group and control group,40 cases in each group.The control group was adopted clomiphene to make the direct ovulation induction.On the basis,the observation group was took ethinylestradiol and cyproterone acetate.Result：After treatment,the follicle counts and ovarian volume of observation group was significantly lower than those of control group,the difference was statistically significant（P〈0. 05）.The levels of serum LH,T and FSH of observation group were significantly lower than those of control group,the differences were statistically significant（P〈0. 05）.The ovulation rate and pregnancy rate of observation group were 82.5% and 32.5% while the rate of control group were 52.5% and 17.5%,the differences were statistically significant（P〈0. 05）.Conclusion：For patients with PCOS and sterility,the ovulation induction based on ethinylestradiol and cyproterone acetate combined with clomiphene can effectively reduce the levels of serum sex hormone,recover the menstrual cycle,accelerate the ovulation and improve the pregnancy rate.It has a higher value of clinical promotion and application.